View Older Stories View More Recent Stories

Apr 20, 2017 09:00AM Merck Donates $300,000 to Support Neglected Tropical Disease Elimination Efforts in Africa
Apr 19, 2017 08:06AM Merck (MRK) Announces 25 Data Presentations at ECCMID
Apr 19, 2017 08:00AM Merck Underscores Continued Commitment to Fighting Infectious Diseases With More than 25 Data Presentations at ECCMID 2017
Apr 18, 2017 08:00AM Togo Becomes First Country in Africa to Validate the Elimination of Lymphatic Filariasis as a Public Health Problem
Apr 18, 2017 08:00AM Togo Becomes First Country in Africa to Validate the Elimination of Lymphatic Filariasis as a Public Health Problem
Apr 10, 2017 04:30PM Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors
Apr 7, 2017 07:31AM Merck (MRK) Receives CRL from FDA for TECOS Study with Sitagliptin
Apr 7, 2017 07:30AM Merck Receives Complete Response Letter from the U.S. FDA for TECOS Study with Sitagliptin
Apr 6, 2017 10:00AM Merck Receives 2017 ENERGY STAR Sustained Excellence Award from U. S. Environmental Protection Agency
Apr 5, 2017 06:53AM Merck (MRK) to Present New Data on ZEPATIER and Investigational Combination Therapy MK-3682B at Liver Congress
Apr 5, 2017 06:50AM Merck to Present New Data on ZEPATIER® (elbasvir and grazoprevir) and Investigational Combination Therapy MK-3682B for the Treatment of Chronic Hepatitis C Infection at The International Liver Congre
Apr 3, 2017 07:16AM Ziopharm Oncology (ZIOP), Merck (MRK) & Intrexon (XON) Announce Development Update on CAR-T Therapy for Cancer
Apr 3, 2017 06:45AM Merck to Hold First-Quarter 2017 Sales and Earnings Conference Call on May 2
Mar 31, 2017 07:02AM Incyte (INCY), Merck (MRK) Provide Details on Pact to Investigate Epacadostat and KEYTRUDA
Mar 31, 2017 07:00AM Incyte and Merck Provide Additional Details on Previously Announced Collaboration Investigating Epacadostat and KEYTRUDA® (pembrolizumab)
Mar 24, 2017 08:14AM Merck (MRK) Announces EMA's CHMP Recommends Approval of KEYTRUDA to Treat Classical Hodgkin Lymphoma
Mar 24, 2017 08:13AM European Medicines Agency’s CHMP Recommends Approval of Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
Mar 23, 2017 05:35PM Pfizer (PFE) and Merck (MRK) BioPharma Unit Get FDA Approval for BAVENCIO® (Avelumab), the 1st Immunotherapy Approved for Metastatic Merkel Cell Carcinoma
Mar 23, 2017 05:30PM FDA Grants Approval for BAVENCIO® (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma
Mar 22, 2017 04:05PM Merck Animal Health Completes Acquisition of Vallée S.A.
Mar 14, 2017 05:07PM Merck (MRK) Announces FDA Approval for KEYTRUDA to Treat Patients with Refractory cHL or Relapses
Mar 14, 2017 05:05PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment, or Who Have Relapsed After Three or More Prior Lines o
Mar 14, 2017 04:45PM Merck (MRK) Provides Update on sBLA for KEYTRUDA in Previously Treated Advanced MSI-H
Mar 14, 2017 04:43PM Merck Provides Update on Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Previously Treated Advanced Microsatellite Instability-High Cancer
Mar 8, 2017 06:12AM 'It's like kumbaya': Trump's genial private meetings with CEOs jar with public attacks
Mar 6, 2017 08:02AM Merck (MRK), Pfizer (PFE) Announce FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines
Mar 6, 2017 08:00AM Merck and Pfizer Announce U.S. FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines for Adults with Type 2 Diabetes
Feb 28, 2017 01:47PM Merck Announces Second-Quarter 2017 Dividend
Feb 28, 2017 01:00PM Recent Survey Finds Many Adults with Diabetes Unaware of Their Increased Risk for Certain Serious Illnesses
Feb 26, 2017 12:30PM Merck’s Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in Bone Marrow Transplant Recipients, Highly Effective Through Week 24 Post-Transplant in
Feb 24, 2017 04:02PM Merck (MRK) Says V212 Reduced Incidence of Confirmed HZ Cases in First Phase 3 Trial
Feb 24, 2017 04:00PM In First Phase 3 Trial, Merck’s Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in Immunocompromis
Feb 23, 2017 11:33AM Trump again vows to bring back U.S. jobs, but offers few details
Feb 20, 2017 08:00AM Aptus Health's RxStart(TM) Solution Launches with Electronic Health Record Partners to Engage Providers and Patients at the Point of Care
Feb 16, 2017 08:00AM Merck’s Fight Against Infectious Disease Goes Digital with Launch of ILÚM Health Solutions
Feb 14, 2017 05:03PM Merck (MRK) Stops EPOCH Study of Verubecestat in Mild to Moderate AD on Lack of Efficacy
Feb 14, 2017 05:00PM Merck Announces EPOCH Study of Verubecestat for the Treatment of People with Mild to Moderate Alzheimer’s Disease to Stop for Lack of Efficacy
Feb 14, 2017 04:53PM Merck (MRK) Says Its Phase 3 Trial of Doravirine for HIV-1 Infection Met Primary Efficacy Endpoint
Feb 14, 2017 04:05PM Merck’s Doravirine, an Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) for the Treatment of HIV-1 Infection, Met Primary Efficacy Endpoint in Pivotal Phase 3 Trial
Feb 3, 2017 06:48AM Merck (MRK) Announces FDA Acceptance of Two sBLAs for KEYTRUDA
Feb 3, 2017 06:45AM FDA Accepts Two sBLAs for Merck’s KEYTRUDA® (pembrolizumab) for Locally Advanced or Metastatic Urothelial Cancer in Cisplatin-Ineligible First-Line and Second-Line Post-Platinum Failure Treatment S
Feb 2, 2017 06:45AM Merck Announces Fourth-Quarter and Full-Year 2016 Financial Results
Jan 31, 2017 04:00PM European Commission Approves KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or
Jan 25, 2017 07:00AM Pro Football Hall of Famer and Cancer Survivor Jim Kelly Teams Up with Merck and Leading Cancer Organizations to Launch Your Cancer Game Plan
Jan 20, 2017 04:02PM Bristol-Myers Squibb (BMY), Ono Enter Settlement and License Agreement with Merck (MRK) to Resolve PD-1 Antibody Patent Litigation
Jan 20, 2017 04:01PM Merck Announces Settlement and License Agreement Resolving KEYTRUDA® (pembrolizumab) Patent Litigation
Jan 20, 2017 04:01PM Bristol-Myers Squibb and Ono Pharmaceutical Company Enter Settlement and License Agreement with Merck to Resolve PD-1 Antibody Patent Litigation
Jan 20, 2017 07:24AM Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
Jan 19, 2017 01:30AM MSD for Mothers Commits $10 Million and Business Expertise to the Global Financing Facility to Help End Preventable Deaths of Mothers
Jan 18, 2017 09:00AM Merck Foundation Grant Expands Project ECHO® in Vietnam and India
View More Recent Stories View Older Stories